February 21, 2019
Mallinckrodt drops futher testing of Therakos to treat young patients with Steroid Refractory Acute Graft-versus-Host Disease
Mallinckrodt will drop testing its Therakos in the Phase 3 clinical trial for treating young patients with Steroid Refractory Acute Graft-versus-Host Disease, after the interim results were published.